Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2026)

Revolution Medicines has reported Accumulated Expenses for 8 years, with the latest figure at $248.9 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 117.02% year-over-year to $248.9 million in Q2 2026; TTM through Jun 2026 was $248.9 million, a 117.02% increase from a year earlier, with the FY2025 full-year figure at $209.3 million, up 116.67% from the prior year.
• Accumulated Expenses was $248.9 million for Q2 2026 at Revolution Medicines, up from $192.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $248.9 million in Q2 2026, with the low at $25.5 million in Q1 2022.
• Average Accumulated Expenses over 5 years is $90.5 million, with a median of $71.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses increased 6.22% in 2022, then surged 153.66% in 2023.
• Over 5 years, Accumulated Expenses stood at $29.4 million in 2022, then soared by 153.66% to $74.7 million in 2023, then increased by 29.35% to $96.6 million in 2024, then surged by 116.67% to $209.3 million in 2025, then rose by 18.89% to $248.9 million in 2026.
• The last three Accumulated Expenses figures came in at $248.9 million (Q2 2026), $192.5 million (Q1 2026), and $209.3 million (Q4 2025), per Business Quant data.